288: A small molecular weight antagonist of CXCR3 reduces the severity of experimental idiopathic pneumonia syndrome and improves survival following allogeneic stem cell transplantation  by Deurloo, D.T. et al.
288
A SMALL MOLECULAR WEIGHT ANTAGONIST OF CXCR3 REDUCES THE
SEVERITY OF EXPERIMENTAL IDIOPATHIC PNEUMONIA SYNDROME
AND IMPROVES SURVIVAL FOLLOWING ALLOGENEIC STEM CELL
TRANSPLANTATION
Deurloo, D.T.1, Chaudhary, M.N.1, Olkiewicz, K.M.1, Silva, I.A.1,
Choi, S.W.1, Liu, C.2, Collins, T.L.3, Sullivan, T.J.3, Cooke, K.R.1
1Dept of Pediatrics, Univeristy of Michigan, Ann Arbor, MI; 2Univer-
sity of Florida, Gainesville, FL; 3Amgen, South San Francisco, CA.
BACKGROUND: Idiopathic pneumonia syndrome (IPS) is a
frequently fatal complication after allogeneic stem cell trans-
plantation (allo-SCT) The pathophysiology of IPS involves the
secretion of inﬂammatory cytokines including IFN and TNF

along with the recruitment of donor T cells to the lung. CXCR3
is a chemokine receptor that is expressed on activated Th1/Tc1
T cell subsets and the expression of its ligands CXCL9 (Mig)
and CXCL10 (IP-10) can be induced in a variety of cell types by
IFN alone or in combination with TNF
. OBJECTIVES: We
examined the effects of a small molecular weight antagonist of
CXCR3, AMG487, on donor T cell recruitment to the lung and
overall survival in an established murine SCT model. METH-
ODS: Lethally irradiated bm1 mice received SCT from either
syngeneic (bm1) or allogeneic, MHC class I disparate (B6)
donors. AMG487 was continuously delivered for 14 or 28 days
by an infusion pump that was implanted subcutaneously two
days before SCT. Drug exposure levels were determined in the
sera of mice at day 7 and 14 after implantation. RESULTS: In
pilot experiments, we found that pulmonary mRNA expression
of both CXCR3 and its ligand IP-10 were signiﬁcantly up-
regulated after allo-SCT. Increases were seen as early as week
one, persisted through week six, and were associated with ele-
vated BAL ﬂuid protein levels (IP-10 / Mig) and enhanced cell
surface expression (CXCR3) on lymphocytes inﬁltrating the
lungs of allo-SCT recipients. Subsequently, we found that com-
pared to vehicle treated controls, lung pathology at day 46 was
signiﬁcantly reduced in allo-SCT recipients treated with drug
for 14 days (7.2  0.6 vs. 3.0  0.4). This reduction was
associated with signiﬁcantly decreased BAL cellularity (1.1 
0.1 vs. 0.6  0.1 106) and CD8 T cell inﬁltration, and
correlated with serum drug levels. AMG487 also signiﬁcantly
reduced the severity of GVHD in both the large and small
bowel. Infusion of AMG487 for 28 days resulted in similar
differences between groups, and was associated with improved
survival when SCT parameters were modiﬁed to enhance mor-
tality from GVHD, (67% vs. 17%). CONCLUSIONS: Admin-
istration of AMG487 for as little as 2 weeks around the time of
allo-SCT has profound effects on T cell recruitment to the lung
and GI tract of transplanted mice. Experiments are ongoing to
determine whether the reduction in target tissue injury and
improved survival are accompanied by preservation of graft-
versus-leukemia responses after SCT.
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THE USE OF CDR3 V SPECTRATYPE ANALYSIS TO IDENTIFY GVHD
AND GVL-REACTIVE CD8 T CELL RESPONSES IN A MYELOID LEUKE-
MIA CHALLENGED MINOR H ANTIGEN MISMATCHED MOUSE TRANS-
PLANTATION MODEL
Fanning, S.L.1, Gichuru, L.N.1, Korngold, R.1, Friedman, T.M.1
1Hackensack University Medical Center, Hackensack, NJ.
Allogeneic hematopoietic stem cell transplantation (HSCT) is
currently the most widely used therapy for the treatment of
hematological malignancies. One drawback to this procedure is
the development of graft-versus-host disease (GVHD). It has
been clearly established that donor T cells are primarily respon-
sible for anti-host activity. While removal of donor T cells leads
to decreased incidence and/or severity of GVHD, it is usually
associated with increased incidence of tumor relapse due to the
lack of donor T cells that mediate graft-versus-leukemia (GVL)
effects, eliminating any residual tumor cells surviving cytore-
ductive therapy. Work in our laboratory has focused on identi-
fying host-reactive and tumor-reactive donor T cells based on T
cell receptor V-chain utilization, using complimentarity-de-
termining region-3 (CDR3)-size spectratype analysis. In this
study, we used the MHC-matched, minor antigen mismatched
murine transplantation model (B10.BR3CBA) to characterize
CD8 T cell repertoire responses against alloantigens and tu-
mor antigens in a host-derived myeloid leukemia (MMCBA).
This model is particularly relevant in that it mimics HLA-
matched sibling donor transplants for AML. Spectratype anal-
ysis has revealed that several unique expansions were exhibited
in both the anti-host and anti-tumor responses. The GVL
potential of the donor T cells was initially examined by trans-
planting MMCBA-challenged CBA recipients with unseparated
B10.BR CD8 T cells. Transplanted mice survived signiﬁcantly
longer than those mice that did not receive T cells (MST 42d vs.
MST 20d, p0.005). The GVHD potential of a single V
family was investigated by transplanting B10.BR CD8V11 T
cells, into lethally irradiated CBA mice. All mice receiving V11
T cells succumbed to GVHD by day 56 (MST 40d). Future
experiments will attempt to treat mice with CD8V T cells
that are uniquely skewed in the anti-tumor response in order to
mediate GVL while avoiding the development of GVHD. This
study provides proof of principle that by determining which V
responses are unique to the anti-tumor response, it may be
possible to separate GVHD and GVL effects in vivo by remov-
ing host-reactive donor T cells and/or enriching for tumor-
reactive T cells.
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RAPAMYCIN-GENERATED TH2 CELL THERAPY OF ESTABLISHED ACUTE
MURINE GVHD REQUIRES TH2 CELL SECRETION OF BOTH IL-4 AND
IL-10
Foley, J.E.1, Mariotti, J.1, Borenstein, T.1, Han, S.1, Eckhaus, M.1,
Fowler, D.1 1Experimental Transplantation and Immunology Branch,
National Cancer Institute, National Institutes of Health, Bethesda, MD.
We have recently shown that rapamycin-generated donor Th2
cells (Th2.rapa cells) can prevent or treat murine acute GVHD
(Foley et al, JI, 2005). Treatment of established GVHD may be
a favorable strategy, as potent GVT effects can be generated
with subsequent GVHD reduction. In this study, we evaluated
the capacity of Th2.rapa cells to treat 14-day established acute
GVHD (B6-into-BALB/c model), the effect of Th2.rapa ther-
apy on a GVT effect against host-type breast cancer cells (TS/A
cells), and whether the anti-GVHD effect required Th2 cell
secretion of Th2 cytokines, IL-4 and IL-10. On day 0, each
transplant cohort received 10106 donor marrow cells, 0.1 
106 host-type TS/A cells, and 15-20106 donor splenic T cells.
This model was stringent, as 20-40% of GVHD controls died
by d14 post-BMT. To evaluate our hypotheses, experimental
cohorts received additional donor T cells on d14 post-BMT that
consisted of ex vivo generated wild-type (WT) Th2.rapa cells,
or IL-4 or IL-10 deﬁcient (KO) Th2.rapa cells. The sum scores
of gut, liver, and skin GVHD by histology analysis at d19
post-BMT demonstrated that Th2.rapa recipients had reduced
GVHD relative to GVHD controls (6.0  0.5 vs. 10.1  0.6;
p.0021); however, recipients of IL-4 or IL-10 KO Th2.rapa
cells did not have reduced GVHD (histology scores of 10.4 
0.5 and 10.5  1.0, respectively; pNS). The GVT effect was
preserved in Th2.rapa recipients, the number of pulmonary
tumor nodules was reduced relative to tumor controls
(p0.0002) and not signiﬁcantly different from GVHD con-
trols. Finally, Th2.rapa recipients had increased survival relative
to GVHD controls (median survival, 33.7  0.4 d vs. 24.8 
1.2 d; p0.0002); in contrast, recipients of IL-4 and IL-10 KO
Th2.rapa cells did not have increased survival (median survivals
of 28.9  .34 d and 24.6  0.2 d; pNS). As such, delayed
infusion of rapamycin-generated donor Th2.rapa cells reduces
established acute GVHD through a mechanism dependent upon
IL-4 and IL-10 secretion without abrogating the GVT effect.
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